Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Recruiting · NCT06947993 · Interventional (participants receive a specific treatment) · Lead sponsor: Novartis Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
GHZ339Placebo
What this trial is about
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- f the master protocol:
- Able and willing to sign the informed consent (IC)
- Patients with a diagnosis of AD and onset of disease for at least 1 year
- Moderate to severe AD
- Key
Exclusion criteria
- f the master protocol:
- Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- Participant with any other active inflammatory skin disease
- Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
- Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
- Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
Where it is running
60 locations listed across 13 US states.
- Novartis Investigative Site - Birmingham, Alabama, United States
- Novartis Investigative Site - Birmingham, Alabama, United States
- Novartis Investigative Site - Fort Smith, Arkansas, United States
- Novartis Investigative Site - Fountain Valley, California, United States
- Novartis Investigative Site - Los Angeles, California, United States
- Novartis Investigative Site - Sacramento, California, United States
- Novartis Investigative Site - Santa Ana, California, United States
- Novartis Investigative Site - Santa Monica, California, United States
- Novartis Investigative Site - Washington D.C., District of Columbia, United States
- Novartis Investigative Site - Miami, Florida, United States
- Novartis Investigative Site - St. Petersburg, Florida, United States
- Novartis Investigative Site - Atlanta, Georgia, United States
- Novartis Investigative Site - Macon, Georgia, United States
- Novartis Investigative Site - Louisville, Kentucky, United States
- Novartis Investigative Site - Brighton, Massachusetts, United States
- Novartis Investigative Site - Troy, Michigan, United States
- Novartis Investigative Site - Saint Joseph, Missouri, United States
- Novartis Investigative Site - Portsmouth, New Hampshire, United States
- Novartis Investigative Site - Brooklyn, New York, United States
- Novartis Investigative Site - Arlington, Texas, United States
- Novartis Investigative Site - Cypress, Texas, United States
- Novartis Investigative Site - Dallas, Texas, United States
- Novartis Investigative Site - Houston, Texas, United States
- Novartis Investigative Site - San Antonio, Texas, United States
- Novartis Investigative Site - Alicante, Spain
- Novartis Investigative Site - Bad Bentheim, Germany
- Novartis Investigative Site - Bardejov, Slovakia
- Novartis Investigative Site - Beijing, China
- Novartis Investigative Site - Beijing, China
- Novartis Investigative Site - Brest, France
- Novartis Investigative Site - Budapest, Hungary
- Novartis Investigative Site - Budapest, Hungary
- Novartis Investigative Site - Dresden, Germany
- Novartis Investigative Site - Fukuoka, Japan
- Novartis Investigative Site - Granada, Spain
- Novartis Investigative Site - Hamburg, Germany
- Novartis Investigative Site - Heidelberg, Germany
- Novartis Investigative Site - Kaohsiung City, Taiwan
- Novartis Investigative Site - Katowice, Poland
- Novartis Investigative Site - Komárno, Slovakia
- Novartis Investigative Site - Košice, Slovakia
- Novartis Investigative Site - Košice, Slovakia
- Novartis Investigative Site - Kyoto, Japan
- Novartis Investigative Site - Las Palmas GC, Spain
- Novartis Investigative Site - Lille, France
- Novartis Investigative Site - Liverpool, United Kingdom
- Novartis Investigative Site - Lodz, Poland
- Novartis Investigative Site - London, United Kingdom
- Novartis Investigative Site - Lorient, France
- Novartis Investigative Site - Lublin, Poland
- Novartis Investigative Site - Madrid, Spain
- Novartis Investigative Site - Madrid, Spain
- Novartis Investigative Site - Magdeburg, Germany
- Novartis Investigative Site - Münster, Germany
- Novartis Investigative Site - Oldenburg, Germany
- Novartis Investigative Site - Paris, France
- Novartis Investigative Site - Pierre-Bénite, France
- Novartis Investigative Site - Plzen Bory, Czechia
- Novartis Investigative Site - Pontevedra, Spain
- Novartis Investigative Site - Prague, Czechia
Showing 60 of 105 listed sites. See the official record for the complete list.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →